What is Promis Neuroscie's earnings per share (EPS)?

Promis Neuroscie (PMN) reported diluted earnings per share of $-22.61 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Promis Neuroscie Financials

PMN

Source SEC Filings (10-K/10-Q) Updated Mar 25, 2026 Currency USD FYE March

This page shows Promis Neuroscie (PMN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.71x

For every $1 of reported earnings, Promis Neuroscie generates $0.71 in operating cash flow (-$28.1M OCF vs -$39.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$39.7M

YoY-1529.3%

Promis Neuroscie reported -$39.7M in net income in fiscal year 2025. This represents a decrease of 1529.3% from the prior year.

EPS (Diluted)

$-22.61

Promis Neuroscie earned $-22.61 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 20654.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

Promis Neuroscie had 9M shares outstanding in fiscal year 2025. This represents a decrease of 72.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$33.4M

YoY+213.8%

Promis Neuroscie invested $33.4M in research and development in fiscal year 2025. This represents an increase of 213.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

PMN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21
Revenue	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$33.4M+213.8%	$10.6M+34.9%	$7.9M-51.0%	$16.1M+247.7%	$4.6M
SG&A Expenses	$6.8M+9.7%	$6.2M-3.0%	$6.4M-12.5%	$7.3M+99.1%	$3.7M
Operating Income	-$40.2M-138.7%	-$16.8M-18.0%	-$14.3M+39.0%	-$23.4M-182.0%	-$8.3M
Interest Expense	N/A	N/A	N/A	$282K-32.2%	$416K
Income Tax	N/A	$0	$0	$0	N/A
Net Income	-$39.7M-1529.3%	$2.8M+121.0%	-$13.2M+26.9%	-$18.1M-84.5%	-$9.8M
EPS (Diluted)	$-22.61	$0.11+110.3%	$-1.07+55.6%	$-2.41-42.6%	$-1.69

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$9.8M+12.0%	$8.7M+60.1%	$5.5M	N/A	$2.6M+57.7%	$1.6M-23.4%	$2.1M	N/A
SG&A Expenses	$2.0M+36.1%	$1.4M-28.1%	$2.0M	N/A	$1.9M+72.0%	$1.1M-29.9%	$1.6M	N/A
Operating Income	-$11.8M-15.4%	-$10.2M-36.5%	-$7.5M	N/A	-$4.4M-63.4%	-$2.7M+26.2%	-$3.7M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	$77K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$11.6M-14.5%	-$10.1M-37.7%	-$7.3M	N/A	$9.3M+453.5%	-$2.6M+27.8%	-$3.6M	N/A
EPS (Diluted)	$-0.24+17.2%	$-0.29-38.1%	$-0.21	N/A	$0.31+338.5%	$-0.13+31.6%	$-0.19	N/A

PMN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21
Total Assets	N/A	$18.9M+38.9%	$13.6M+96.7%	$6.9M-61.0%	$17.7M
Current Assets	N/A	$18.9M+38.9%	$13.6M+97.3%	$6.9M-61.0%	$17.7M
Cash & Equivalents	N/A	$13.3M+5.5%	$12.6M+114.4%	$5.9M-65.3%	$16.9M
Inventory	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$2.4M-75.4%	$9.9M+19.3%	$8.3M-31.6%	$12.1M
Current Liabilities	N/A	$2.2M-76.3%	$9.3M+45.8%	$6.4M+590.3%	$929K
Long-Term Debt	N/A	N/A	$0	N/A	$3.9M
Total Equity	N/A	$16.5M+339.3%	$3.8M+378.5%	-$1.3M-123.8%	$5.7M
Retained Earnings	N/A	-$90.7M+3.0%	-$93.5M-16.5%	-$80.3M-29.0%	-$62.2M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$21.5M+125.6%	$9.5M-30.3%	$13.6M-27.8%	$18.9M-22.8%	$24.5M+1638.8%	$1.4M-60.3%	$3.5M-73.9%	$13.6M
Current Assets	$21.5M+125.6%	$9.5M-30.3%	$13.6M-27.8%	$18.9M-22.8%	$24.5M+1638.8%	$1.4M-60.3%	$3.5M-73.9%	$13.6M
Cash & Equivalents	$15.4M+241.4%	$4.5M-46.1%	$8.4M-37.1%	$13.3M-38.3%	$21.5M+2070.0%	$992K-60.3%	$2.5M-80.2%	$12.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$12.3M+24.0%	$9.9M+136.9%	$4.2M+72.3%	$2.4M-85.9%	$17.2M+367.6%	$3.7M+6.2%	$3.5M-64.8%	$9.9M
Current Liabilities	$12.2M+24.3%	$9.8M+142.2%	$4.1M+82.8%	$2.2M-15.8%	$2.6M-16.9%	$3.2M+19.9%	$2.6M-71.7%	$9.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Total Equity	$9.2M+2501.4%	-$383K-104.0%	$9.5M-42.6%	$16.5M+126.7%	$7.3M+419.4%	-$2.3M-3053.4%	$77K-97.9%	$3.8M
Retained Earnings	-$119.7M-10.7%	-$108.2M-10.3%	-$98.0M-8.1%	-$90.7M-0.3%	-$90.4M+9.3%	-$99.7M-2.7%	-$97.1M-3.9%	-$93.5M

PMN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	-$28.1M-3.4%	-$27.2M-150.7%	-$10.8M+36.3%	-$17.0M-83.1%	-$9.3M
Capital Expenditures	N/A	N/A	N/A	$2K-67.2%	$6K
Free Cash Flow	N/A	N/A	N/A	-$17.0M-83.0%	-$9.3M
Investing Cash Flow	-$702-1.3%	-$693+48.6%	-$1K+31.9%	-$2K-102.1%	$95K
Financing Cash Flow	$20.9M-24.9%	$27.9M+57.1%	$17.7M+173.3%	$6.5M-74.6%	$25.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$10.1M-160.9%	-$3.9M+21.8%	-$4.9M+43.5%	-$8.7M-30.6%	-$6.7M-343.4%	-$1.5M+85.4%	-$10.3M-173.8%	-$3.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	$470K-98.3%	$27.2M	$0-100.0%	$190K+137.3%	-$511K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PMN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	16.9%+368.9pp	-352.0%	N/A	-173.0%
Return on Assets	N/A	14.7%+111.7pp	-97.0%+163.8pp	-260.8%-205.7pp	-55.2%
Current Ratio	N/A	8.52+7.1	1.46+0.4	1.08-18.0	19.07
Debt-to-Equity	N/A	0.15+0.1	0.00+6.1	-6.14-6.8	0.69
FCF Margin	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-126.0%	N/A	-77.6%	N/A	127.5%	N/A	-4714.8%	N/A
Return on Assets	-54.0%+52.4pp	-106.4%-52.6pp	-53.8%	N/A	37.8%+224.0pp	-186.1%-83.7pp	-102.5%	N/A
Current Ratio	1.76+0.8	0.97-2.4	3.36-5.2	8.52-0.8	9.30+8.9	0.44-0.9	1.34-0.1	1.46
Debt-to-Equity	1.34+27.2	-25.86-26.3	0.44+0.3	0.15-2.2	2.37+4.0	-1.62-46.6	45.02+45.0	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Q32 BIO INC QTTB

$93.3M

Curis CRIS

$22.0M

Elevation Oncolo ELEV

$21.6M

Lisata Therapeutics Inc LSTA

$45.3M

Akari Therapeutics Plc AKTX

$5.1M

Frequently Asked Questions

Is Promis Neuroscie profitable?

No, Promis Neuroscie (PMN) reported a net income of -$39.7M in fiscal year 2025.

What is Promis Neuroscie's operating cash flow?

Promis Neuroscie (PMN) generated -$28.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

How much does Promis Neuroscie spend on research and development?

Promis Neuroscie (PMN) invested $33.4M in research and development during fiscal year 2025.

How many shares does Promis Neuroscie have outstanding?

Promis Neuroscie (PMN) had 9M shares outstanding as of fiscal year 2025.

Are Promis Neuroscie's earnings high quality?

Promis Neuroscie (PMN) has an earnings quality ratio of 0.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.